The invention provides formulations, dosage forms, and treatments comprising cyclohexane polyalcohol compounds that provide beneficial pharmacokinetic profiles in the treatment of a disorder and/or disease including a disorder in protein folding and/or aggregation, and/or amyloid formation, deposition, accumulation, or persistence. In aspects of the invention, a dosage form is provided comprising an amount of a cyclohexane polyalcohol compound suitable for administration to a subject to provide a therapeutically effective concentration of the compound in plasma, brain and/or cerebral spinal fluid and a pharmaceutically acceptable carrier, diluent or excipient. The formulation can be administered in a dose of 500, 1000, 2000, 3500, 5000 or 7000 mg of cyclohexane polyalcohol compound to achieve a mean plasma concentration profile having a mean AUC.sub.0-INF in .mu.h/mL of, respectively, 43.+-.20%, 130.+-.20%, 215.+-.20%, 467.+-.20%, 507.+-.20% or 885.+-.20%, and having a mean C.sub.max in .mu.mL of, respectively, 5.8.+-.20%, 17.+-.20%, 33.+-.20%, 75.+-.20%, 110.+-.20% or 155.+-.20%.